Biogen R&D head Alfred Sandrock to retire Dec 31, 2021; interim named

BIOGEN INC.

Alfred W. Sandrock, Head of R&D, will retire effective Dec 31, 2021, after 23 years at Biogen.
Priya Singhal, Head of Global Safety & Regulatory Sciences, will serve as interim R&D head.
Sandrock led development of key drugs: Tysabri, Tecfidera, Spinraza, Plegridy, and Aduhelm.
Biogen has launched a search for a permanent successor.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Alfred W. Sandrock, Jr., M.D., Ph.D.

Head of Research & Development

BIIB · BIOGEN INC.

Effective: 2021-12-31
Filed: November 17, 2021, 6:59 PM ET

On November 15, 2021, Biogen Inc. (the “Company”) issued a press release announcing that Alfred W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company, effective December 31, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alfred W. Sandrock, Jr., M.D., Ph.D. departed as Head of Research & Development at BIOGEN INC..

Action: retire
Role: Head of Research & Development

Exact text from the filing

On November 15, 2021, Biogen Inc. (the “Company”) issued a press release announcing that Alfred W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company, effective December 31, 2021.

View on SEC.gov

BIOGEN INC. filing history →

Source: SEC EDGAR

accession 0001193125-21-331813

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.